1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Resources from Teva for your practice and patients

Teva is committed to helping MS professionals and the relapsing MS community

VIEW CNE SERVICES

Teva offers a range of downloadable educational resources that you can share with your patients

EXPLORE RESOURCES Download Prescribing Information

Teva offers customizable tools that let your patients track their COPAXONE® injections instantly and efficiently

COPAXONE iTracker®

COPAXONE iTracker®

Developed to help patients schedule doses, track injection site rotations, and more. COPAXONE iTracker® helps patients manage their COPAXONE® injections.

LEARN MORE
COPAXONE® (glatiramer acetate injection)  40 mg/mL webTracker™ Icon

COPAXONE webTracker®

Allows patients to track injections on the Web and automatically syncs with COPAXONE iTracker® app.

LEARN MORE
Do your patients have questions about COPAXONE®?
DOWNLOAD THIS GUIDE
Why Teva's COPAXONE® complex manufacturing process is one your patients can trust
LEARN HOW IT'S MADE

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×